Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care

R: A Language and Environment for Statistical Computing

R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works

Membrane transporters in drug development

The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340 · see citing works

<i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · see citing works

Statin-associated myopathy

Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463 · see citing works

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · see citing works

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

Genest, J. J., McPherson, R., Frohlich, J. J., Anderson, T. J., Campbell, N. R. C., Carpentier, A. C., Couture, P., Dufour, R., Fodor, G. J., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 758 · see citing works

Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans

Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682 · see citing works

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 636 · see citing works

Polymorphisms in OATP-C

Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 625 · see citing works

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

Wang, D., Guo, Y., Wrighton, S. A., Cooke, G., & Sadée, W. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 507 · see citing works

Health, United States, 2010; with special feature on death and dying

Bernstein, A. B., Bilheimer, L. T., & Makuc, D. M. (2011) · Cited by 498 · see citing works

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

LEE, E., RYAN, S., Birmingham, B. K., Zalikowski, J. A., March, R. E., Ambrose, H., MOORE, R., Lee, C. G. L., CHEN, Y., & Schneck, D. W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480 · see citing works

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470 · see citing works

Narrative review: statin-related myopathy

Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453 · see citing works

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 433 · see citing works

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 417 · see citing works

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409 · see citing works

Drug Transporters in Drug Efficacy and Toxicity

DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359 · see citing works

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper‐DeHoff, R. M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.57 · Cited by 332 · see citing works

Transporter Pharmacogenetics and Statin Toxicity

Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.197 · Cited by 329 · see citing works

Robust Replication of Genotype-Phenotype Associations across Multiple Diseases in an Electronic Medical Record

Ritchie, M. D., Denny, J. C., Crawford, D. C., Ramirez, A. H., Weiner, J., Pulley, J. M., Basford, M., Brown-Gentry, K. D., Balser, J. R., Masys, D. R., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.03.003 · Cited by 320 · see citing works

Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.

Kempen, H. J. M., Glatz, J. F. C., Leuven, J. A. G., van der Voort, H. A., & Katan, M. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38456-x · Cited by 304 · see citing works

Genetic Variability in CYP3A5 and its Possible Consequences

Xie, H.-G., Wood, A. J. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.243.29833 · Cited by 300 · see citing works

Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial

Chasman, D. I., Giulianini, F., MacFadyen, J., Barratt, B. J., Nyberg, F., & Ridker, P. M. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.961144 · Cited by 285 · see citing works

An Assessment of Statin Safety by Muscle Experts

Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 263 · see citing works

Antiepileptic Drugs Increase Plasma Levels of 4β-Hydroxycholesterolin Humans

Bodin, K., Brétillon, L., Aden, Y., Bertilsson, L., Broomé, U., Einarsson, C., & Diczfalusy, U. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105127200 · Cited by 241 · see citing works

Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

Mann, D., Reynolds, K., Smith, D. A., & Muntner, P. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l181 · Cited by 222 · see citing works

P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations

Cascorbi, I. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_6 · Cited by 203 · see citing works

4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

Diczfalusy, U., Nylén, H., Elander, P., & Bertilsson, L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03773.x · Cited by 202 · see citing works

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., Bailey, D. G., Stein, C. M., & Kim, R. B. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3280ef698f · Cited by 198 · see citing works

Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS

Honda, A., Yamashita, K., Hara, T., Ikegami, T., Miyazaki, T., Shirai, M., Xu, G., Numazawa, M., & Matsuzaki, Y. (2008) · Journal of Lipid Research · doi:10.1194/jlr.d800040-jlr200 · Cited by 193 · see citing works

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

Martin, P. D. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80316-8 · Cited by 191 · see citing works

Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response

Mougey, E. B., Feng, H., Castro, M., Irvin, C. G., & Lima, J. J. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32831bd98c · Cited by 191 · see citing works

Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8)

Letschert, K., KEPPLER, D. O. R., & König, J. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114744.08559.92 · Cited by 187 · see citing works

Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers

Chung, J., Cho, J., YU, K., Kim, J., Oh, D., JUNG, H., Lim, K. S., MOON, K., SHIN, S., & Jang, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170 · see citing works

Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS

Honda, A., Yamashita, K., Miyazaki, H., Shirai, M., Ikegami, T., Xu, G., Numazawa, M., Hara, T., & Matsuzaki, Y. (2008) · Journal of Lipid Research · doi:10.1194/jlr.d800017-jlr200 · Cited by 164 · see citing works

ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

Keskitalo, J. E., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.25 · Cited by 148 · see citing works

ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin

Tomlinson, B., Hu, M., Lee, V. W. Y., Lui, S. S. H., Chu, T. T. W., Poon, E. W. M., Ko, G. T. C., Baum, L., Tam, L., & Li, E. K. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.232 · Cited by 143 · see citing works

Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage

Wilke, R. A., Moore, J. H., & Burmester, J. K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200506000-00007 · Cited by 131 · see citing works

Polymorphisms of human cytochrome P450 2C9 and the functional relevance

Zhou, S.-F., Zhou, Z.-W., & Huang, M. (2009) · Toxicology · doi:10.1016/j.tox.2009.08.013 · Cited by 119 · see citing works

Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) Transporters in the Intestine, Liver and Kidney

Zaïr, Z. M., Eloranta, J. J., Stieger, B., & Kullak-Ublick, G. A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.597 · Cited by 114 · see citing works

Weighing the benefits of high-dose simvastatin against the risk of myopathy

Egan, A., & Colman, E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1106689 · Cited by 113 · see citing works

Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2)

Gradhand, U., & Kim, R. B. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952617 · Cited by 109 · see citing works

Combinatorial Pharmacogenetics

Wilke, R. A., Reif, D. M., & Moore, J. H. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1874 · Cited by 108 · see citing works

Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction

Bailey, K. M., Romaine, S. P. R., Jackson, B. M., Farrin, A. J., Efthymiou, M., Barth, J. H., Copeland, J., McCormack, T., Whitehead, A. L., Flather, M. D., et al. (2010) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.109.898502 · Cited by 106 · see citing works

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Martin, P. D., Dane, A. L., Nwose, O. M., Schneck, D. W., & Warwick, M. J. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002237987 · Cited by 91 · see citing works

Effect of Age and Gender on Pharmacokinetics of Atorvastatin in Humans

Gibson, D. M., Bron, N. J., Richens, M. A., Hounslow, N. J., Sedman, A. J., & Whitfield, L. R. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04194.x · Cited by 90 · see citing works

Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity

Schwarz, U. I., zu Schwabedissen, H. E. M., Tirona, R. G., Suzuki, A., Leake, B. F., Mokrab, Y., Mizuguchi, K., Ho, R. H., & Kim, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328342f5b1 · Cited by 90 · see citing works

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Martín, P., Dane, A. L., Nwose, O. M., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401382722 · Cited by 69 · see citing works

Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2‐/‐ Mice and Intraindividual Variability in Human Subjects

DeGorter, M. K., Urquhart, B. L., Gradhand, U., Tirona, R. G., & Kim, R. B. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011422815 · Cited by 33 · see citing works

Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis

Cuyper, I. D., Wolthers, B. G., van Doormaal, J. J., & Wijnandts, P. N. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90203-g · Cited by 14 · see citing works

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443 · see citing works

The pharmacology of statins

Sirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 705 · see citing works

ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017

Faludi, A., Izar, M. C. D. O., Saraiva, J., Chacra, A., Bianco, H. T., Neto, A. A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A. C., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 660 · see citing works

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., Maxwell, W. D., McLeod, H. L., Krauss, R. M., Roden, D. M., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.125 · Cited by 434 · see citing works

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370 · see citing works

The complex molecular genetics of familial hypercholesterolaemia

Berberich, A. J., & Hegele, R. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0052-6 · Cited by 298 · see citing works

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)

Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 253 · see citing works

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components

Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 201 · see citing works

Statin drug interactions and related adverse reactions: an update

Bellosta, S., & Corsini, A. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1394455 · Cited by 179 · see citing works

Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update

Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173 · see citing works

Drug–drug–gene interactions and adverse drug reactions

Malki, M. A., & Pearson, E. R. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0122-0 · Cited by 169 · see citing works

Statins: a viable candidate for host-directed therapy against infectious diseases

Parihar, S. P., Guler, R., & Brombacher, F. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0094-3 · Cited by 155 · see citing works

Current and Emerging Uses of Statins in Clinical Therapeutics: A Review

Davies, J. T., Delfino, S., Feinberg, C. E., Johnson, M. F., Nappi, V. L., Olinger, J. T., Schwab, A., & Swanson, H. I. (2016) · Lipid Insights · doi:10.4137/lpi.s37450 · Cited by 148 · see citing works

CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease

Woolsey, S., Mansell, S. E., Kim, R. B., Tirona, R. G., & Beaton, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065979 · Cited by 135 · see citing works

Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites

Patel, M., Taskar, K. S., & Zamek‐Gliszczynski, M. J. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.671 · Cited by 114 · see citing works

BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications

Hira, D., & Terada, T. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.004 · Cited by 91 · see citing works

Pharmacogenomics of statins: understanding susceptibility to adverse effects

Kitzmiller, J., Mikulik, E., Dauki, A. M., Mukherjee, C., & Luzum, J. A. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s86013 · Cited by 92 · see citing works

Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders

Singh, S., Sarma, D. K., Verma, V., Nagpal, R., & Kumar, M. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.064 · Cited by 94 · see citing works

Muscle- and skeletal-related side-effects of statins: tip of the iceberg?

Auer, J., Sinzinger, H. F., Franklin, B., & Berent, R. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550804 · Cited by 85 · see citing works

Treatment Options for Statin-Associated Muscle Symptoms

Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 83 · see citing works

Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights

Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83 · see citing works

Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters

Teft, W. A., Morse, B. L., Leake, B. F., Wilson, A. S., Mansell, S. E., Hegele, R. A., Ho, R. H., & Kim, R. B. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00937 · Cited by 83 · see citing works

Pharmacogenetics of Statin-Induced Myotoxicity

Kee, P. S., Chin, P. K. L., Kennedy, M. A., & Maggo, S. D. S. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.575678 · Cited by 72 · see citing works

The Role of Next-Generation Sequencing in Pharmacogenetics and PharmacogenomicsPreprint

Schwarz, U. I., Gulilat, M., & Kim, R. B. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033027 · Cited by 76 · see citing works

Pharmacogenetics of statins treatment: Efficacy and safety

Guan, Z., Wu, K., Li, R., Yin, Y., Li, X., Zhang, S., & Li, Y. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13025 · Cited by 71 · see citing works

Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence

Brunham, L. R., Baker, S. K., Mammen, A. L., Mancini, G. B. J., & Rosenson, R. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy119 · Cited by 71 · see citing works

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions

Hahn, M., & Roll, S. C. (2021) · Pharmaceuticals · doi:10.3390/ph14050487 · Cited by 66 · see citing works

Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2

Ferrari, M., Guasti, L., Maresca, A. M., Mirabile, M., Contini, S., Grandi, A. M., Marino, F., & Cosentino, M. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1661-6 · Cited by 66 · see citing works

LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL

Chapman, M. J., Orsoni, A., Tan, R., Mellett, N. A., Nguyen, A., Robillard, P., Giral, P., Thérond, P., & Meikle, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p119000543 · Cited by 65 · see citing works

Cardiovascular Pharmacogenomics: Expectations and Practical Benefits

Turner, R. M., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.234 · Cited by 63 · see citing works

CYP3A activity: towards dose adaptation to the individual

Hohmann, N., Haefeli, W. E., & Mikus, G. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1163337 · Cited by 59 · see citing works

Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1

Medwid, S. J., Li, M. M. J., Knauer, M. J., Lin, K., Mansell, S. E., Schmerk, C. L., Zhu, C., Griffin, K. E., Yousif, M. D., Dresser, G. K., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087619 · Cited by 51 · see citing works

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid

Choi, H. Y., Bae, K.-S., Cho, S.-H., Ghim, J.-L., Choe, S., Jung, J. A., Jin, S.-J., Kim, H.-S., & Lim, H.-S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000176 · Cited by 49 · see citing works

Identification of Glycochenodeoxycholate 3‐O‐Glucuronide and Glycodeoxycholate 3‐O‐Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers

Neuvonen, M., Hirvensalo, P., Tornio, A., Rago, B., West, M. A., Lazzaro, S., Mathialagan, S., Varma, M. V. S., Cerny, M. A., Costales, C., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2053 · Cited by 49 · see citing works

Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry

Duarte, R. R. R., Copertino, D. C., Iñiguez, L., Marston, J. L., Bram, Y., Han, Y., Schwartz, R. E., Chen, S., Nixon, D. F., & Powell, T. R. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00356-6 · Cited by 49 · see citing works

A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites

Turner, R. M., Fontana, V., Zhang, J. E., Carr, D. F., Yin, P., Fitzgerald, R. J., Morris, A. P., & Pirmohamed, M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1820 · Cited by 48 · see citing works

The pharmacogenomics of statins

Gelissen, I. C., & McLachlan, A. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.12.002 · Cited by 47 · see citing works

A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy

Turongkaravee, S., Jittikoon, J., Lukkunaprasit, T., Sangroongruangsri, S., Chaikledkaew, U., & Thakkinstian, A. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00208-w · Cited by 45 · see citing works

SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study

Liu, J., Liu, X., Chen, S., Zhang, Y., Cai, L., Yang, M., Lai, W., Ren, B., & Zhong, S. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2318-z · Cited by 44 · see citing works

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient ( LDLR +/− and LDLR −/− ) Yucatan Miniature Pigs

Burke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Barrett, P. H. R., Newton, R. S., Pickering, J. G., & Huff, M. W. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310676 · Cited by 46 · see citing works

Cannabis Pharmacogenomics: A Path to Personalized Medicine

Babayeva, M., & Loewy, Z. G. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040228 · Cited by 41 · see citing works

Statin Responses in Chinese Patients

Tomlinson, B., Chan, P., & Liu, Z.-M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.40204 · Cited by 41 · see citing works

A Pharmacometabonomic Approach To Predicting Metabolic Phenotypes and Pharmacokinetic Parameters of Atorvastatin in Healthy Volunteers

Huang, Q. B., Aa, J., Jia, H., Xin, X., Tao, C., Liu, L., Zou, B., Song, Q., Shi, J., Cao, B., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00440 · Cited by 38 · see citing works

Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium

Sposito, A. C., Faria‐Neto, J. R., de Carvalho, L. S. F., Lorenzatti, A. J., Cafferata, A., Elikir, G. D., Esteban, E., Villegas, E. C. M., Bodanese, L. C., Rodrigo Alonso, K., et al. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1252740 · Cited by 38 · see citing works

Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

Hu, M., & Tomlinson, B. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.851667 · Cited by 37 · see citing works

An update on efflux and uptake transporters as determinants of statin response

Rocha, K. C. E., Pereira, B. M. V., & Rodrigues, A. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482276 · Cited by 37 · see citing works

Opportunities and Challenges in Cardiovascular Pharmacogenomics

Roden, D. M., Driest, S. L. V., Wells, Q. S., Mosley, J. D., Denny, J. C., & Peterson, J. F. (2018) · Circulation Research · doi:10.1161/circresaha.117.310965 · Cited by 38 · see citing works

Statin intolerance

Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 37 · see citing works

Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population

Kadam, P., Ashavaid, T. F., Ponde, C. K., & Rajani, R. M. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12369 · Cited by 37 · see citing works

Applications for pharmacogenomics in pharmacy practice: A scoping review

Hayashi, M., Hamdy, D. A., & Mahmoud, S. H. (2021) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2021.08.009 · Cited by 38 · see citing works

The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis

Song, Y., Lim, H.-H., Yee, J., Yoon, H.-Y., & Gwak, H. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030501 · Cited by 36 · see citing works

Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants

Kitzmiller, J. P. (2014) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000128 · Cited by 35 · see citing works

Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?

Alfonsi, J., Hegele, R. A., & Gryn, S. E. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0573-6 · Cited by 35 · see citing works

The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?

Benes, L. B., Bassi, N. S., & Davidson, M. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.001 · Cited by 35 · see citing works

Effectiveness of high dose dexamethasone in the treatment of acute stroke.

Ogun, S. A., & Odusote, K. A. (2001) · PubMed · Cited by 35 · see citing works

Rosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 Cells

Salunkhe, V. A., Elvstam, O., Eliasson, L., & Wendt, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151592 · Cited by 33 · see citing works

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability

Zubiaur, P., Benedicto, M. D., Villapalos‐García, G., Navares‐Gómez, M., Mejía-Abril, G. P., Román, M. C., Martín‐Vílchez, S., Ochoa, D., & Abad‐Santos, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030204 · Cited by 33 · see citing works

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia

Maxwell, W. D., Ramsey, L. B., Johnson, S. G., Moore, K. G., Shtutman, M. S., Schoonover, J. H., & Kawaguchi‐Suzuki, M. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1981 · Cited by 32 · see citing works

The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control

Sankaralingam, S., Kim, R. B., & Padwal, R. S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.10.025 · Cited by 32 · see citing works

Potential statin drug interactions in elderly patients: a review

Damiani, I., Corsini, A., & Bellosta, S. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1822324 · Cited by 31 · see citing works

Myopathy Associated With Statins and SGLT2 – A Review of Literature

Gupta, R., Alcantara, R., Popli, T., Mahajan, S., Tariq, U., Dusaj, R., & Malik, A. H. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100765 · Cited by 31 · see citing works

Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring

Ryan, T. P., Morrison, R. D., Sutherland, J. J., Milne, S. B., Ryan, K. A., Daniels, J. S., Misra‐Hebert, A. D., Hicks, J. K., Vogan, E. D., Teng, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185471 · Cited by 31 · see citing works

Role of Genetic Variations in the Hepatic Handling of Drugs

Marı́n, J. J. G., Serrano, M. A., Monte, M. J., Sánchez-Martín, A., Temprano, Á. G., Briz, Ó., & Romero, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082884 · Cited by 30 · see citing works

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

Goss, G. D., Jonker, D. J., Laurie, S. A., Weberpals, J. I., Oza, A. M., Spaans, J. N., la Porte, C., & Dimitroulakos, J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0836-6 · Cited by 30 · see citing works

Introduction to Clinical Pharmacology

Tirona, R. G., & Kim, R. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00020-x · Cited by 28 · see citing works

Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children

Kyler, K. E., Wagner, J. B., Hosey, C. M., Watt, K., & Shakhnovich, V. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00352-8 · Cited by 29 · see citing works

Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report

Brailovski, E., Kim, R. B., & Juurlink, D. N. (2020) · Annals of Internal Medicine · doi:10.7326/l20-0549 · Cited by 28 · see citing works

Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults

Kanukula, R., Salam, A., Rodgers, A., & Kamel, B. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00978-9 · Cited by 28 · see citing works

Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease

Tirona, R. G., Kassam, Z., Strapp, R., Ramu, M., Zhu, C., Liu, M., Schwarz, U. I., Kim, R. B., Al‐Judaibi, B., & Beaton, M. D. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079624 · Cited by 28 · see citing works

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation

Wu, T., Wu, S., Li, L., Xiang, J., Wang, N., Chen, W., & Zhang, J. (2023) · Human Genomics · doi:10.1186/s40246-023-00506-3 · Cited by 27 · see citing works

Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates

Medwid, S. J., Price, H. R., Taylor, D. P., Mailloux, J., Schwarz, U. I., Kim, R. B., & Tirona, R. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713567 · Cited by 25 · see citing works

In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1)

Russell, L. E., Zhou, Y., Lauschke, V. M., & Kim, R. B. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01200 · Cited by 24 · see citing works

Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy

Ahangari, N., Doosti, M., Ghayour‐Mobarhan, M., Sahebkar, A., Ferns, G. A., & Pasdar, A. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1800074 · Cited by 24 · see citing works

Pharmacogenomics, Lipid Disorders, and Treatment Options

Gryn, S. E., & Hegele, R. A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.82 · Cited by 23 · see citing works

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia

Ma, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23 · see citing works

New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk

Klose, G., Beil, F. U., Dieplinger, H., von Eckardstein, A., Föger, B., Gouni‐Berthold, I., Heigl, F., Köenig, W., Kostner, G. M., Landmesser, U., et al. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0513-9 · Cited by 23 · see citing works

Is personalized medicine a dream or a reality?

Morse, B. L., & Kim, R. B. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.950407 · Cited by 23 · see citing works

Exploring the impact of pharmacogenetics on personalized medicine: A systematic review

Álvarez, L. A., Ramos, J., & Calleja‐Hernández, M. Á. (2024) · Farmacia Hospitalaria · doi:10.1016/j.farma.2023.12.004 · Cited by 22 · see citing works

Development and characterization of nano-emulsions and nano-emulgels for transdermal delivery of statins

Sithole, M. N., Marais, S., Maree, S. M., Plessis, D., du Plessis, J., & Gerber, M. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1867533 · Cited by 22 · see citing works

Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol

Karmaus, P. W. F., Shi, M. Y., Perl, S., Biancotto, A., Candia, J., Cheung, F., Kotliarov, Y., Young, N. S., & Fessler, M. B. (2019) · JCI Insight · doi:10.1172/jci.insight.131530 · Cited by 21 · see citing works

Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space

Unger, M. S., Mudunuru, J., Schwab, M. G., Hopf, C., Drewes, G., Nies, A. T., Zamek‐Gliszczynski, M. J., & Reinhard, F. B. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00897 · Cited by 21 · see citing works

Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer

Chen, C. Y., Wu, H., Kong, D., Xu, Y., Zhang, Z., Chen, F., Zou, L., Li, Z., Jin, S., Luo, H., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7810 · Cited by 19 · see citing works

Statin Safety in Chinese: A Population-Based Study of Older Adults

Li, D. Q., Kim, R. B., McArthur, E., Fleet, J. L., Hegele, R. A., Shah, B. R., Weir, M. A., Molnar, A. O., Dixon, S. N., Tu, J. V., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150990 · Cited by 18 · see citing works

Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox

Özvegy‐Laczka, C., Ungvári, O., & Bakos, É. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115448 · Cited by 18 · see citing works

The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations

Schweitzer, A. M., Gingrich, M. A., Hawke, T. J., & Rebalka, I. A. (2020) · European Journal of Applied Physiology · doi:10.1007/s00421-020-04360-2 · Cited by 18 · see citing works

Transcriptional Regulation of MECP2E1-E2 Isoforms and BDNF by Metformin and Simvastatin through Analyzing Nascent RNA Synthesis in a Human Brain Cell Line

Buist, M., Fuss, D., & Rastegar, M. (2021) · Biomolecules · doi:10.3390/biom11081253 · Cited by 18 · see citing works

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP

Chapman, M. J., Orsoni, A., Robillard, P., Thérond, P., & Giral, P. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.001 · Cited by 18 · see citing works

Pharmacogenetic Loci for Rosuvastatin are Associated with Intima-Media Thickness Change and Coronary Artery Disease Risk

Кононов, С. И., Маль, Г. С., Azarova, I. E., Klyosova, E. Y., Быканова, М. А., Churnosov, M. I., & Polonikov, A. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0097 · Cited by 17 · see citing works

Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug

Soko, N. D., Masimirembwa, C. M., & Dandara, C. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0114 · Cited by 17 · see citing works

An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites

Pilon, M., Leclair, G., Oussaïd, E., St‐Jean, I., Jutras, M., Gaulin, M., Mongrain, I., Busseuil, D., Rouleau, J. L., Tardif, J., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13318 · Cited by 16 · see citing works

Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice

Shahabi, P., & Dubé, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.02.025 · Cited by 16 · see citing works

Plasma Drug Concentrations of Orally Administered Rosuvastatin in Hispaniolan Amazon Parrots (Amazona ventralis)

Beaufrère, H., Papich, M. G., Brandão, J., Nevarez, J. G., & Tully, T. N. (2015) · Journal of Avian Medicine and Surgery · doi:10.1647/2014-015 · Cited by 16 · see citing works

Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder

Sukasem, C., Medhasi, S., Pasomsub, E., Vanwong, N., Ngamsamut, N., Puangpetch, A., Chamnanphon, M., Hongkaew, Y., Limsila, P., & Pinthong, D. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s101580 · Cited by 16 · see citing works

Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention

Turner, R. M., Fontana, V., Fitzgerald, R. J., Morris, A. P., & Pirmohamed, M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14133 · Cited by 16 · see citing works

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE’s multiethnic population

Alqasrawi, M. N., Al-Mahayri, Z. N., Albawa’neh, A. S., Khasawneh, L. Q., Dabaghie, L., Altoum, S. M., Hamza, D., Misra, V., Ouda, H. Z., Aburuz, S., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00753-6 · Cited by 15 · see citing works

A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications

Shorbaji, A. M., Pushparaj, P. N., Al-Ghafari, A. B., Mira, L. S., Basabrain, M. A., Naseer, M. I., Ahmed, F., Abu-Elmagd, M. M., Rasool, M., & Bakhashab, S. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00511-6 · Cited by 15 · see citing works

A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance

Bigossi, M., Maroteau, C., Dawed, A. Y., Taylor, A., Srinivasan, S., Melhem, A. L., Pearson, E. R., Pola, R., Palmer, C. N. A., & Siddiqui, M. K. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad040 · Cited by 15 · see citing works

Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study

Lalatović, N., Ždralević, M., Antunović, T., & Pantović, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-44792-2 · Cited by 15 · see citing works

A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease

Kristiansen, O., Vethe, N. T., Fagerland, M. W., Bergan, S., Munkhaugen, J., & Husebye, E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14122 · Cited by 14 · see citing works

Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease

Zhang, J., Liu, N., & Yang, C. (2020) · Panminerva Medica · doi:10.23736/s0031-0808.18.03475-4 · Cited by 15 · see citing works

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability

Zubiaur, P., Benedicto, M. D., Villapalos‐García, G., Navares‐Gómez, M., Mejía-Abril, G. P., Román, M. C., Martín‐Vílchez, S., Ochoa, D., & Abad‐Santos, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030204 · Cited by 33 · see citing works

Genetic Polymorphisms in Drug Transporter Genes (ABCB1, OATP1B1) and Their Impact on Statin Pharmacokinetics and Myopathy RiskPreprint

Alrohaimi, A. H. (2026) · Preprints.org · doi:10.20944/preprints202601.0803.v1

Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites

Bai, X., Zhang, B., Wang, P., Wang, G., Li, J., Wen, D., Long, X.-Z., Sun, H., Liu, Y., Huang, M., et al. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0013-y · Cited by 31 · see citing works

Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

Birmingham, B. K., Bujac, S. R., Elsby, R., Azumaya, C. T., Wei, C., Chen, Y., Mosqueda-Garcia, R., & Ambrose, H. J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1801-z · Cited by 153 · see citing works

The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people

Wang, Y., Tian, Y., Lv, P.-Y., Chen, L., Luo, W., Jing, X., Li, H., Tan, Z., Wang, Y., Zhou, H., et al. (2017) · Die Pharmazie · doi:10.31083/ph.2017.6944 · Cited by 13 · see citing works